LSX RNA Leaders Europe Congress, Basel

This week, our Research Director, Marc Watson, will be at the LSX RNA Leaders Europe Congress in Basel, Switzerland, March 4-6, to meet with key innovators in RNA therapeutics.

At Harness Therapeutics, we use the power of antisense oligonucleotides to enable precision protein control, unlocking previously undruggable targets early in the disease pathway to transform neurodegenerative disease treatment. Our lead FAN1 programme in Huntington's Disease directly addresses the underlying disease mechanisms.

If you're attending RNA Leaders and are interested in discussing our approach to modulating protein translation, let's connect!

#Harness #Biotech #Neuroscience #RNALeaders #Huntingtonsdisease #Neurodegenerativediseases

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Our news

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

January 2025

Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of transformational neurodegeneration pipeline

September 2024

Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director

View all